重组人DNA损伤诱导转录因子4在恶性肿瘤中的研究进展  

Research progress on recombinant human DNA damage induced transcription factor 4 in malignant tumors

作　　者：曹淑云 王季石[1,2] CAO Shuyun;WANG Jishi(The Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou 550004,China;Guizhou Medical University,Guiyang,Guizhou 550004,China)

机构地区：[1]贵州医科大学附属医院,贵阳550004 [2]贵州医科大学,贵阳550004

出　　处：《重庆医学》2025年第4期972-976,共5页Chongqing Medical Journal

基　　金：国家自然科学基金项目(82170168);贵州省自然科学基金项目(黔科合基础〔2023〕382号)。

摘　　要：重组人DNA损伤诱导转录因子4(DDIT4)是一个在应激条件下激活的反应基因,参与细胞生长、凋亡、代谢和氧化应激。近年来,关于DDIT4在肿瘤发生、发展中的作用机制研究取得重要进展,已证实其参与调控肿瘤细胞凋亡、增殖、迁移和侵袭等过程,同时参与肿瘤微环境重塑、自噬调控及耐药形成等多个关键生物学过程。靶向DDIT4有望成为抑制肿瘤发生、发展进程的有效治疗选择。该文就DDIT4在癌症中的作用及其调节机制的相关研究进展予以综述。DNA damage-inducible transcript 4(DDIT4)is a gene activated under stress conditions,participating in cell growth,apoptosis,metabolism,and oxidative stress.In recent years,significant progress has been made in the research on the mechanism of DDIT4 in tumorigenesis and development.It has been confirmed that it is involved in regulating processes such as apoptosis,proliferation,migration and invasion of tumor cells,and is also involved in multiple key biological processes such as tumor microenvironment remodeling,autophagy regulation and drug resistance formation.Targeting DDIT4 may potentially become an effective therapeutic option for inhibiting the tumorigenesis and tumour progression.Targeting DDIT4 is expected to be an effective therapeutic option to inhibit the tumorigenesis and progression.This article reviews the research progress on the role and regulatory mechanisms of DDIT4 in cancer.

关 键 词：重组人DNA损伤诱导转录因子4 恶性肿瘤 肿瘤微环境 自噬 化疗耐药 

分 类 号：R73.3[医药卫生—肿瘤]